Welcome to our dedicated page for Passage Bio news (Ticker: PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio stock.
Passage Bio, Inc. (NASDAQ: PASG) delivers cutting-edge gene therapies targeting rare central nervous system disorders through innovative AAV vector technology. This news hub provides investors and researchers with timely updates on clinical advancements, strategic partnerships, and operational developments shaping the company's trajectory in genetic medicine.
Access authoritative reporting on PASG's lead programs including PBGM01 for GM1 gangliosidosis and PBFT02 for frontotemporal dementia. Our curated news collection features regulatory milestones, trial data disclosures, and analysis of licensing agreements with academic and industry partners.
Key updates cover three critical areas: clinical trial progress across neurodegenerative targets, research collaborations enhancing therapeutic platforms, and strategic operational decisions supporting sustainable development. Bookmark this page for consolidated access to PASG's evolving position in gene therapy innovation.
Passage Bio (Nasdaq: PASG) has granted an inducement award of options to purchase 82,000 shares of its common stock to a new employee, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.05 per share, matching the closing price on the grant date, April 17, 2023. The options will vest over four years, with 25% vesting on the one-year anniversary and the remaining in 36 equal monthly installments, subject to continued employment. The company focuses on developing therapies for central nervous system disorders, including GM1 gangliosidosis and frontotemporal dementia, and has a collaboration with the University of Pennsylvania’s Gene Therapy Program. Further details about its gene therapy pipeline can be found on their official website.
Passage Bio, a clinical stage genetic medicines company focused on central nervous system (CNS) disorders, announced that its CEO William Chou, M.D., and CTO Alex Fotopoulos will participate in a virtual fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on April 24, 2023, at 3:30 p.m. ET.
The event will be accessible via a live webcast on the company’s website, with a replay available for 30 days after. Passage Bio is dedicated to developing therapies for CNS diseases, currently advancing clinical programs in GM1 gangliosidosis and frontotemporal dementia, and has a robust preclinical pipeline targeting amyotrophic lateral sclerosis and Huntington’s disease. The company collaborates with the University of Pennsylvania’s Gene Therapy Program, enhancing its research capabilities and access to innovative gene therapy candidates.
Passage Bio (NASDAQ: PASG), a clinical stage genetic medicines company, announced that CEO William Chou, M.D., will take part in a fireside chat at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days on April 3, 2023, at 3:55 p.m. ET in New York. A live webcast of the chat will be available on the company's Investors & Media section. Passage Bio focuses on developing transformative therapies for central nervous system (CNS) disorders, including GM1 gangliosidosis and frontotemporal dementia, with strong collaborations enhancing their research capabilities.
Passage Bio (NASDAQ: PASG) reported promising interim data for PBGM01 in GM1 gangliosidosis during the 19th Annual WORLDSymposium™, showing a biological effect in the first six patients. The company plans to expand the Imagine-1 study to include higher doses and expects initial safety data from Cohort 4 by mid-2023. Financial results highlighted a cash position of $189.6 million, sufficient to fund operations through the first half of 2025. The net loss for Q4 2022 stood at $27.1 million, while R&D expenses decreased to $17.7 million. The company anticipates key results from its upliFT-D trial in FTD by late 2023.
Passage Bio, a clinical-stage genetic medicines company (Nasdaq: PASG), announces the opening of its Tachi Yamada Scholarship program for rising juniors majoring in life sciences at Pennsylvania colleges. The $10,000 scholarship, awarded annually, aims to support students committed to careers in life sciences. Applications are due by April 1, 2023, for the initial award in fall 2023. The scholarship honors the legacy of Dr. Tachi Yamada, co-founder and former chairman of the board, who championed mentorship in the field. The selected scholar will also receive mentorship opportunities over two years for professional development.
